| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/26/2005 | WO2005046573A2 Pro104 ANTIBODY COMPOSITIONS AND METHODS OF USE |
| 05/26/2005 | WO2005046572A2 Targeted delivery of controlled release polymer systems |
| 05/26/2005 | WO2005046561A2 Multilayer dosage form comprising a matrix that influences release of a modulatory substance |
| 05/26/2005 | WO2005046449A2 Soluble tcr molecules and methods of use |
| 05/26/2005 | WO2005020901A3 Delivery of a therapeutic agent in a formulation for reduced toxicity |
| 05/26/2005 | WO2005016246A3 Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases |
| 05/26/2005 | WO2005014024A3 Conjugates of a polymer and a protein linked by an oxime linking group |
| 05/26/2005 | WO2005012488A3 Compositions for encapsulation and controlled release |
| 05/26/2005 | WO2005010048A3 Rg1 antibodies and uses thereof |
| 05/26/2005 | WO2005002626A3 Therapeutic phosphonate compounds |
| 05/26/2005 | WO2004096826A3 Method for selective inhibition of human n-myc gene in n-myc expressing tumors through antisense and antigen peptido-nucleic acids (pna) |
| 05/26/2005 | WO2004091538B1 Homogeneous, thermoreversible alginate films and soft capsules made therefrom |
| 05/26/2005 | WO2004089421A3 Methods for rational pegylation of proteins |
| 05/26/2005 | WO2004042068A3 Injectable and bioadhesive polymeric hydrogels as well as related methods of enzymatic preparation |
| 05/26/2005 | WO2004004667A3 Method of immunotherapy |
| 05/26/2005 | WO2002093998A9 Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof |
| 05/26/2005 | US20050113565 Pegylated factor VII glycoforms |
| 05/26/2005 | US20050113560 Body fluid compatible and biocompatible resin |
| 05/26/2005 | US20050113353 Applying gel containing testosterone |
| 05/26/2005 | US20050113332 Compositions and methods for treating an arthritic condition |
| 05/26/2005 | US20050113329 Contacing cell/body fluid with antibody which binds human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide; for inhibiting tumor growth; gene expression inhibition; immunization |
| 05/26/2005 | US20050113297 Contacting target cell or noncellular molecular entity with phagocytic marker and moiety that binds to a component that is present on or at surface of target cell or noncellular molecular entity, thereby increasing level or density of phagocytic marker on target cell; marker comprises phosphatidylserine |
| 05/26/2005 | US20050113293 Cyclic and linear oligopeptides; capable of increasing gap junction conductance; lack the proarrhythmic side effects; use as drug to also treat eye disorders, cancer, and gastrointestinal disorders among others |
| 05/26/2005 | US20050113289 Conjugate of hemoglobin covalently joined to a polysaccharide; for use as synthetic blood; preventing hemorrhagic shock |
| 05/26/2005 | US20050113288 Bonding tissues and cross-linking proteins with naphthalimide compounds |
| 05/26/2005 | US20050113276 Skin cleaning compounds, body splash, surgical scrub, wound care agents, hand sanitizers, disinfectants, mouthwashes, pet shampoos, hard surface sanitizer; reduction of bacteria, rotavirus, or rhinovirus on skin surface; topical |
| 05/26/2005 | US20050112720 Soluble complexes of amylod beta peptide and peptidyl prolyl isomerase chaperone and methods of making and using them |
| 05/26/2005 | US20050112208 Composition for the treatment of burns, sunburns, abrasions, ulcers and cutaneous irritation |
| 05/26/2005 | US20050112207 Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells |
| 05/26/2005 | US20050112206 Mixture of drug, aminoacrylate polymer and acid |
| 05/26/2005 | US20050112205 Method of encapsulating an active substance |
| 05/26/2005 | US20050112204 micellar poloxamer preparation comprising voriconazole and a single poloxamer; increases solubility and aqueous stability |
| 05/26/2005 | US20050112202 tableting processes and equipment, and improved solid dosage forms for oral delivery of drugs that cause contact irritation or ulceration to the lining of the esophagus and stomach |
| 05/26/2005 | US20050112198 Bupropion formulation for sustained delivery |
| 05/26/2005 | US20050112197 Celecoxib dissolving in polyethylene glycol; antiinflammatory agents, osteoporosis, respiratory system disorders, antitumor agents, analgesics |
| 05/26/2005 | US20050112191 Novel formulations comprising lipid-regulating agents |
| 05/26/2005 | US20050112187 Nucleic acid that expresses a polypeptide such as a cytokine and a phospholipid, both having cytotoxic activity; synergistic combination; side effect reduction |
| 05/26/2005 | US20050112182 Medical adhesive and medical covering agent using ultraviolet ray curable chitosan derivative |
| 05/26/2005 | US20050112181 By transdermal administration of testosterone in a hydroalcoholic gel; unique pharmacokinetic steady-state profile |
| 05/26/2005 | US20050112177 Gelled composition of whey protein and other beneficial constituents; shelf life; easy to use form |
| 05/26/2005 | US20050112176 Forming a gelled whey protein by processing a mixture of whey protein and other selected ingredients at an appropriate temperature and pH; bioavailable; packaged and easy to store and transport; shelf life |
| 05/26/2005 | US20050112175 Drug delivery device |
| 05/26/2005 | US20050112151 Skin adherent hydrogels |
| 05/26/2005 | US20050112143 Method of developing an immunogenic composition and HIV vaccine |
| 05/26/2005 | US20050112140 Immunogenic composition and method of developing a vaccine based on portions of the HIV matrix protein |
| 05/26/2005 | US20050112139 Immunogenic composition and method of developing a vaccine based on factor H binding sites |
| 05/26/2005 | US20050112092 Stable, aerosolizable suspensions of proteins in ethanol |
| 05/26/2005 | US20050112089 Conjugate of biodegradable aliphatic polyester with TAT 49-57 peptide or peptide chain containing TAT 49-57 peptide and nanoparticle manufactured using the same |
| 05/26/2005 | US20050112088 Water solubility; polymer joining active materials |
| 05/26/2005 | US20050112087 Pharmaceutical formulations for sustained drug delivery |
| 05/26/2005 | US20050112081 Liquid compositions comprising oxyalkylated polyglycerol esters |
| 05/26/2005 | US20050112021 Reduction of Contaminants In Blood and Blood Products Using Photosensitizers and Peak Wavelengths of Light |
| 05/26/2005 | CA2805859A1 Il-18 binding proteins |
| 05/26/2005 | CA2549737A1 Polysaccharide-containing composition and tear film stabilizing ophthalmic solution |
| 05/26/2005 | CA2546115A1 Solid dispersions or solid dispersion pharmaceutical preparations of phenylalanine derivatives |
| 05/26/2005 | CA2545841A1 Use of lipopeptides for activating t lymphocytes through the skin |
| 05/26/2005 | CA2545679A1 Biotin-facilitated transport in gram negative bacteria |
| 05/26/2005 | CA2545454A1 Adenocarcinoma specific antibody sam-6, and uses thereof |
| 05/26/2005 | CA2545276A1 Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer |
| 05/26/2005 | CA2545066A1 A reagent system and method for modifying the luminescence of lanthanide(iii) macrocyclic complexes |
| 05/26/2005 | CA2544814A1 Non-symmetrical gelling agent |
| 05/26/2005 | CA2544487A1 Multilayer pharmaceutical form with a matrix which influences the delivery of a modulatory substance |
| 05/26/2005 | CA2544483A1 Soluble tcr fusion molecules and methods of use |
| 05/26/2005 | CA2530605A1 Pro104 antibody compositions and methods of use |
| 05/26/2005 | CA2512657A1 Protein complex using immunoglobulin fragment and method for the preparation thereof |
| 05/25/2005 | EP1533300A1 Organic amine salts of glutamic acid derivatives and their application |
| 05/25/2005 | EP1532988A2 Antibody dye conjugates for the intraoperative delimitation of tumors |
| 05/25/2005 | EP1532986A2 Pharmaceutical composition for treatment of rhinitis |
| 05/25/2005 | EP1532983A1 Immunoglobulin preparations having increased stability |
| 05/25/2005 | EP1532981A1 Stable eye drops containing latanoprost as the active ingredient |
| 05/25/2005 | EP1532974A2 Aqueous gel comprising 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
| 05/25/2005 | EP1532149A2 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments |
| 05/25/2005 | EP1531869A2 Compositions and methods for treating cancer using maytansinoid cd44 antibody immunoconjugates and chemotherapeutic agents |
| 05/25/2005 | EP1531868A2 Therapeutic agent-containing polymeric nanoarticles |
| 05/25/2005 | EP1531867A1 Metastable pharmaceutical compositions |
| 05/25/2005 | EP1531866A1 Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids |
| 05/25/2005 | EP1531863A2 Antibody-avidin fusion proteins as cytotoxic drugs |
| 05/25/2005 | EP1531862A1 Stabilized liquid anti-rsv antibody formulations |
| 05/25/2005 | EP1531859A1 Compositions and methods for transepithelial molecular transport |
| 05/25/2005 | EP1531851A2 Covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins and methods of use |
| 05/25/2005 | EP1531847A2 Pharmaceutical formulation |
| 05/25/2005 | EP1531846A2 Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use |
| 05/25/2005 | EP1531844A2 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances |
| 05/25/2005 | EP1531837A1 Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions |
| 05/25/2005 | EP1531835A2 Micelle assemblies |
| 05/25/2005 | EP1531814A1 Sustained-release tablet composition of pramipexole |
| 05/25/2005 | EP1531805A1 Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
| 05/25/2005 | EP1531803A1 Method of inhibiting prostate cancer cell proliferation |
| 05/25/2005 | EP1531800A2 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s) |
| 05/25/2005 | EP1531799A1 Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"), novel combinations thereof as well as manufacturing of these pharmaceutical compositions |
| 05/25/2005 | EP1531797A1 Biodegradable block copolymeric compositions for drug delivery |
| 05/25/2005 | EP1531796A2 Microparticles with adsorbed polypeptide-containing molecules |
| 05/25/2005 | EP1531795A1 Formulations limiting spread of pulmonary infections |
| 05/25/2005 | EP1531793A1 Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent |
| 05/25/2005 | EP1531757A2 Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from |
| 05/25/2005 | EP1531687A1 Stable emulsions of oils in aqueous solutions and methods for producing same |
| 05/25/2005 | EP1411908B1 Nitrogen oxide generating compositions for the treatment of subungual infections |
| 05/25/2005 | EP1397095A4 Abuse resistant opioid containing transdermal systems |
| 05/25/2005 | EP1322286B1 Polymeric delivery formulations of leuprolide with improved efficacy |
| 05/25/2005 | EP1214059B1 Surface modified particulate compositions of biologically active substances |